Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1960935 | 1.00 | GCK (0.55) | GCKABL1KMT2AJAK3PTGS2 | |
| SCHEMBL1959058 | 0.92 | GCK (0.56) | GCKABL1KMT2APTGS2ATR | |
| SCHEMBL1959057 | 0.92 | GCK (0.56) | GCKABL1KMT2APTGS2ATR | |
| SCHEMBL1959396 | 0.91 | GCK (0.53) | GCKKMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL1959397 | 0.91 | GCK (0.53) | GCKKMT2APDE3BPDE3AP2RY12 | |
| SCHEMBL1961701 | 0.90 | GCK (0.59) | GCKABL1KMT2AJAK3PTGS2 | |
| SCHEMBL1961702 | 0.90 | GCK (0.59) | GCKABL1KMT2AJAK3PTGS2 | |
| SCHEMBL1962902 | 0.89 | GCK (0.58) | GCKKMT2AJAK3PTGS2PTGS1 | |
| SCHEMBL1962903 | 0.89 | GCK (0.58) | GCKKMT2AJAK3PTGS2PTGS1 | |
| SCHEMBL1959072 | 0.88 | GCK (0.55) | GCKABL1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513103-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-8222416-B2 | Azaindole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2011073117-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144105-A1 | AZAINDOLE GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GCK 1/4885ABL1 2649/4885KMT2A 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.